We've merged with Palleos Healthcare to form a wide-reaching European CRO.
Find out more
OCT Clinical, a leading CRO from Eastern Europe, teamed up with UK-based Futura Medical to conduct the FM71 study. This study evaluated the innovative MED3000 topical gel for the treatment of erectile dysfunction (ED). The confirmatory trial successfully enrolled 100 male participants with diverse demographics across four countries – Poland, Georgia, the USA, and Bulgaria. Efficiently completed and ahead of schedule, the study marks a significant advancement in ED treatment options. It showcases how a CRO’s expertise in managing complex, multi-national clinical trials can contribute to the success of a study.
Download the full text to learn more about the outcomes of this study.
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.
